We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
- Authors
Florakis, Dimos; Hung, Victor; Kaltsas, Gregory; Coyte, Donna; Jenkins, Paul J.; Chew, Shern L.; Grossman, Ashley B.; Besser, G. Michael; Monson, John P.
- Abstract
OBJECTIVETo study the effects of short (6 months) and longer-term (up to 24 months) growth hormone (GH) replacement therapy using a dose titration regimen, on lipid and glucose metabolism in GH-deficient, hypopituitary adults. DESIGNOn-going open study of GH treatment up to 24 months. Measurements were performed at baseline and at 6, 12, 18 months and 2 years during therapy (data shown at 6 months and 2 years only). Using a dose titration regimen the median GH dose used to achieve and maintain IGF-I levels above the median, but below the upper limit of the age-related reference range (median IGF-I 202.5 μg/l, range 76–397 μg/l), was 1.2 IU daily (range 0.4–3 IU) [0.8 IU/day, males; 1.6 IU/day, females]. PATIENTSNinety GH-deficient hypopituitary adults (54 female, median age 48 years, range 19–79 years) entered the study and 24 (14 female, median age 45 years, range 32–79 years) have concluded the 2 year period of assessment. MEASUREMENTSBody mass index (BMI), waist and hip circumference ratio (WHR), fasting lipids, glucose and glycated haemoglobin (HbA1c) levels were measured at 6 month intervals during GH therapy. RESULTSUsing the dose titration regimen, compared to pretreatment values, total and low density lipoprotein (LDL)-cholesterol levels were significantly lower at 6 months (mean ± SEM, 5.61 ± 0.1 vs. 5.25 ± 0.1, and 3.85 ± 0.19 vs. 3.43 ± 0.26, respectively, P < 0.05), and were maintained throughout the study. Male patients had significantly lower pretreatment total and LDL cholesterol levels than females (mean ± SEM, 5.33 ± 0.16 mmol/l vs. 5.7 ± 0.12 mmol/l and 3.8 ± 0.23 mmol/l vs. 3.92 ± 0.29 mmol/l, respectively, P < 0.05). A decrease in total cholesterol was confined to patients with pretreatment total cholesterol levels above 5.8 mmol/l; patients with the highest pretreatment cholesterol levels (> 6.4 mmol/l) obtained the greatest cholesterol...
- Subjects
PITUITARY necrosis; SOMATOTROPIN; LIPIDS; GLUCOSE
- Publication
Clinical Endocrinology, 2000, Vol 53, Issue 4, p453
- ISSN
0300-0664
- Publication type
Article
- DOI
10.1046/j.1365-2265.2000.01108.x